Partial Peroxisome Proliferator-Activated Receptor Agonist Angiotensin Receptor Blockers | Zendy

Amytis Towfighi | Zendy; Bruce Ovbiagele | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Partial Peroxisome Proliferator-Activated Receptor Agonist Angiotensin Receptor Blockers

Author(s) -

Amytis Towfighi,

Bruce Ovbiagele

Publication year - 2008

Publication title -

cerebrovascular diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.221

H-Index - 104

eISSN - 1421-9786

pISSN - 1015-9770

DOI - 10.1159/000139656

Subject(s) - medicine , insulin resistance , agonist , dyslipidemia , peroxisome proliferator activated receptor , partial agonist , ppar agonist , angiotensin ii , stroke (engine) , receptor , pharmacology , diabetes mellitus , endocrinology , insulin , engineering , mechanical engineering

Although their primary mechanism of action is blood pressure lowering, emerging data suggest that select angiotensin receptor blockers (ARBs), which partially activate the peroxisome proliferator-activated receptor gamma (PPAR-gamma), may effectively treat insulin resistance and dyslipidemia without the toxicity sometimes associated with full PPAR-gamma agonists. Since up to 50% of the patients with ischemic stroke and transient ischemic attack harbor insulin resistance, drugs that simultaneously control hypertension and insulin resistance could be particularly useful for stroke prevention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research